BIOA B — BioArctic AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK26.00bn
- SEK24.10bn
- SEK2.00bn
Brief: Leqembi Included In China's Commercial Insurance Innovative Drug List
Brief: Bioarctic Says Leqembi-Data Suggests Potential To Delay Disease Progression
Brief: BioArctic Says New Drug Application For Subcutaneous Formulation Of Leqembi Submitted In Japan
Brief: Bioarctic Says Leqembi Approved For IV Maintenance Treatment In United Kingdom
Brief: BioArctic Q3 Operating Profit SEK -28.8 Million
Brief: Bioarctic AB Says Health Canada Grants Authorization For Leqembi® (Lecanemab)
Brief: Bioarctic Leqembi® Approved For Iv Maintenance Treatment In China
Brief: BioArctic's Leqembi Approved For Treatment Of Early Alzheimer's Disease In Australia
Brief: BioArctic Says Founders Intend To Divest Minor Part Of Their Shareholding
Brief: BioArctic says Rolling Sbla Initiated To U.S. FDA For Leqembi® Iqlik™ As Subcutaneous Starting Dose For Early Alzheimer's Disease Treatment Under Fast Track Status
Brief: BioArctic Says Rolling sBLA Initiated To The U.S. FDA For Leqembi As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Disease Under Fast Track Status
Brief: US FDA Approves Leqembi® IQKLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
Brief: US FDA Approves Leqembi® IQKLIK ™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
Brief: Bioarctic CEO Gunilla Osswald Disposed SEK 600,851 Worth Of Co Shares On Aug 28
Brief: BioArctic Q2 Operating Profit SEK 179.1 Million
Brief: Bioarctic And Novartis Sign Option, Collaboration And License Agreement
Brief: Q2 Sales Of Leqembi Bring BioArctic SEK 162.5 Mln In Royalty
Brief: Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review
Brief: Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU